“…Three studies used a quasi-randomized design [10,14,41], six were patient-randomized trials [12,15,18,37,38,42], and four were cluster-randomized trials [11,13,16,17]. Two studies were ongoing [38,41], and two others were methodological papers describing the study protocol [37,42]. Interventions included educational material for patients (eight studies) [11-14, 16, 18, 37, 41], physician notification of patients' osteoporosis and fracture risk (eight studies) [10,11,14,15,18,37,38,41], patient notification of osteoporosis and fracture risk (six studies) [10-13, 17, 41], patient counseling (four studies) [14,15,18,41], electronic medical record (EMR) prompts for physicians (two studies) [12,13], list of at-risk patients provided to physicians (two studies) [13,17], physician education by academic detailing (two studies) [16,17], arrangements for BMD testing and bisphosphonate prescription by the study physician (one study) [15], a risk assessment tool provided to physicians and discussion of the tool with the study coordinator before appointments with atrisk patients (one study) [42], and peripheral BMD testing by quantitative ultrasound performed by the patient's community pharmacist (one study) [18] …”